Anti-Hyperglycemic and Insulin Sensitizer Effects of Turmeric and Its Principle Constituent Curcumin

Zeinab Ghorbani 1; Azita Hekmatdoost 2; Parvin Mirmiran 2,3,*

1Faculty of Nutrition and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Science, Tehran, IR Iran
2Department of Clinical Nutrition and Dietetics, Faculty of Nutrition Sciences and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
3Nutrition and Endocrine Research Center, Obesity Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
*Corresponding author: Parvin Mirmiran, Nutrition and Endocrine Research Center, Obesity Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, P.O. Box: 19395-4763, Tehran, IR Iran. Tel: +98-2122402463, +98-2122401624, +98-2122402463. E-mail: mirmiran@endocrine.ac.ir

1. Context

1.1. Turmeric or Curcuma longa

1.1.1. Health Benefits

Turmeric is obtained from the plant Curcuma longa L; its major constituent, curcumin, is a polyphenol with multiple effects which can modulate some signaling pathways.

Evidence Acquisition: Insulin resistance is a major risk factor for chronic diseases such as type 2 diabetes, atherosclerotic, metabolic syndrome and cardiovascular disease. In addition, insulin resistance in peripheral tissue is one of the most important reasons of hyperglycemia which can cause global or systemic effects. The present study reviewed studies published in PubMed from 1998 to 2013, indicating the role of curcumin in attenuation of many pathophysiological processes involved in development and progression of hyperglycemia and insulin resistance.

Results: Curcumin can reduce blood glucose level by reducing the hepatic glucose production, suppression of hyperglycemia-induced inflammatory state, stimulation of glucose uptake by up-regulation of GLUT4, GLUT2 and GLUT3 genes expressions, activation of AMP kinase, promoting the PPAR ligand-binding activity, stimulation of insulin secretion from pancreatic tissues, improvement in pancreatic cell function, and reduction of insulin resistance.

Conclusions: Curcumin has antihyperglycemic and insulin sensitizer effects. Thereby, more studies evaluating the effects of curcumin on hyperglycemic state and insulin resistance in related disorders such as diabetes are recommended.

Keywords: Turmeric; Curcumin; Curcuminoids; Curcuma longa; Hyperglycemia; Blood Glucose; Insulin Resistance; Hyperinsulinemia

1.2. Curcumin

Curcumin is a lipophilic polyphenol approximately insoluble in water, but is quite stable in the acidic pH of stomach (5). During the recent decades, polyphenol intakes have been getting greater attention, possibly because of their protective roles against various degenerative diseases such as cardiovascular diseases and cancer (7). Curcumin is a polyphenol with multiple effects which can modulate the biological activity of a number of signaling pathways. Chemical structure of curcumin is 1, 7-bis [4-hydroxy-3-methoxyphenyl]-4, 6-heptadiene-3, 5-dione (Figures 1-3) (4, 6, 8). Chemical structure of curcumin as a component of turmeric or a single supplement plays a role in suppression of platelet aggregation,

Copyright © 2014, Research Institute For Endocrine Sciences and Iran Endocrine Society; Published by Kowsar. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
tumor genesis, metastasis, oxidative processes, inflammatory cytokine production, and myocardial infarction. Curcumin can modulate cystic fibrosis defects, lower cholesterol, suppress diabetes, improve wound healing, enhance multiple sclerosis, and block human immunodeficiency virus (HIV) replication. Moreover, reports also demonstrate the role of curcumin in protection against cataract formation, adriamycin-induced nephrotoxicity, drug or alcohol induced liver injury, and Inflammatory Bowel Disease (IBD) (1). Extensive reports from in vitro and in vivo studies have manifested the molecular basis for pharmaceutical applications of this polyphenol against numerous chronic diseases such as cancer, autoimmune diseases, neurological diseases, metabolic disorders, and pulmonary, liver and cardiovascular diseases (6). Molecular targets of curcumin are summarized in Figure 2 and details follow.

1.2.1. Anti-Inflammatory and Antioxidant Effects of Curcumin

Curcumin is constantly approved as an antioxidant and an anti-inflammatory agent. It seems that the hydroxyl and methoxy groups of curcumin are responsible for such effects (9). Curcumin performs these effects by modulating signaling pathways with many molecular targets (Figure 2) (10). Curcumin down-regulates signaling through the JAK/STAT pathway, which leads to negative regulation of proinflammatory interleukins (IL-1, -2, -6, -8, -12), and cytokines (tumor necrosis factor-alpha (TNF-α), monocyte chemoattractant protein-1 (MCP-1)). Curcumin modulates the inflammatory response by down-regulating the activity of cyclooxygenase-2 (COX-2), lipoxygenase, xanthine oxidase, and inducible nitric oxide synthase (iNOS) enzymes, resulting in inhibition of STAT3 phosphorylation and consequent STAT3 nuclear translocation (8-13). Curcumin inhibitions of COX-2 and iNOS are possibly contributed to suppression of the nuclear factor kappaB (NF-B) activation by this polyphenol. NF-B increases the expression of proinflammatory cytokines genes such as IL-1 and TNF-α and also stimulates the expression of inflammatory process enzymes including iNOS and COX-2 (9). TNF-α up-regulates the gene expression of various inflammatory cytokines which have causal association with hypertension, obesity, and high fasting glucose, decrease insulin sensitivity, and may lead to insulin resistance (IR), type 2 diabetes, and cardiovascular disease (14). Some studies have indicated that the beneficial anti-inflammatory effect of curcumin is mediated by up-regulation of peroxisome proliferator-activated receptor-γ (PPAR-γ) activation (15).

Curcumin stimulates the expression of Nrf2 and HO-1. Nrf2 is expressed in a wide range of tissues, many of which are sites of expression for phase 2 detoxification genes; it binds to the nuclear factor-erythroid derived 2 (NF-E2) binding sites, consisted of a subset of antioxidant response elements (ARE), which is a critical mechanism of protection against free radicals (9).

1.3. Hyperglycemia and Hyperinsulinemia

1.3.1. Insulin Function and Insulin Resistance

Insulin is a hormone with multiple effects. Binding of insulin to the α-subunit of the insulin receptor molecule induces rapid auto-phosphorylation of the β-subunit, which lead to increase of its tyrosine kinase activity. Tyrosine phosphorylation of insulin receptor proteins induces the cytoplasmic binding activity of insulin receptor substrate-1 (IRS-1) to insulin receptor. IRS-1 plays a key role in transmitting signals from insulin receptors to intracellular PI3K/Akt and MAP kinase pathways, which eventually results in the second intracellular step of insulin action (16-18), protein-tyrosine phosphatase 1B (PTP1B), a negative regulator of insulin signaling, which is elevated in obesity, targeting tyrosine-phosphorylated insulin receptor β and IRS-1. Therefore, PTP1B inhibition causes elevated insulin sensitivity and glucose tolerance; thus, inhibition of PTP1B can be a new target in treatment of impaired glucose tolerance and insulin signaling in diabetic patients (16). Some of the substances possibly affecting or playing roles in insulin signaling are shown in Table 1.

IR is a condition in which defects in the action of insulin are such that normal levels of insulin do not operate as the signal for glucose uptake. Pancreas compensates for the decreased insulin response by increasing the insulin secretion; however, the result is hyperinsulinemia to maintain euglycemia. This process will continue until the reserve capacity is surpassed by metabolic demands and insulin secretion is no more sufficient; then, blood glucose concentration rises and glucose intolerance and type 2 diabetes develop (18-20).
Adipocytes decrease glucose uptake in peripheral tissues by release of free fatty acids (FFAs). It seems that FFAs induce IR in muscle at the level of insulin-dependent glucose transport by impairing the insulin-signaling pathway (17, 18). On the other hand, when the serum FFAs concentration rises, signs of chronic inflammation are observed with the release of inflammatory cytokines including TNF-α, IL-6, and IL-1β, which have been implicated in pathogenesis of insulin resistance (17). Furthermore, increased oxidative stress and accumulation of lipid peroxidation metabolites in body, pancreatic beta cell dysfunction, mitochondrial dysfunction, and decreased FA β-oxidation are other factors which can lead to insulin resistance (17, 19).

Therefore, insulin resistance, even in the absence of obesity, is also a major risk factor for related chronic diseases such as type 2 diabetes, atherosclerotic and cardiovascular disease. Insulin resistance is a key component of metabolic syndrome, consisted of a series of risk factors such as abdominal obesity, hypertension, insulin resistance, and dyslipidemia (20).

### 13.2. Hyperglycemia

The process of glucose homeostasis maintains the plasma glucose levels within a narrow range, usually between 60 and 150 mg/dL (17, 18). GLUT-4 is located on cell membranes of muscle cells and adipocytes. Insulin binds to its receptor and initiates a signaling cascade which leads to translocation of GLUT-4 to plasma membrane, thus, permitting the influx of glucose; in the absence of insulin, GLUT-4 in cytosol is surrounded by membrane vesicles (18). Insulin resistance of peripheral tissue, discharge of glycogen storage, changed digestion and absorption of dietary carbohydrate, increased gluconeogenesis

<table>
<thead>
<tr>
<th>Substance</th>
<th>Role in Insulin Signaling</th>
</tr>
</thead>
<tbody>
<tr>
<td>GLUT</td>
<td>Translocated to plasma membrane for glucose influx</td>
</tr>
<tr>
<td>IL-6</td>
<td>Impairs/inhibits insulin signaling; suppresses adipogenesis and secretion of adiponectin</td>
</tr>
<tr>
<td>NF-κB</td>
<td>Influences gene transcription; inhibited by adiponectin</td>
</tr>
<tr>
<td>PPAR-γ</td>
<td>Stimulates free fatty acid (FFA) catabolism; thiazolidinediones (TZDs) are PPAR-γ agonists</td>
</tr>
<tr>
<td>TNFα</td>
<td>Main factor for stimulating the secretion of FFAs from adipose tissue into circulation; impairs insulin signaling</td>
</tr>
<tr>
<td>MCP-1</td>
<td>Impairs insulin-stimulated glucose uptake; promotes atherosclerosis</td>
</tr>
<tr>
<td>FFAs</td>
<td>Adipocytes decrease glucose uptake in peripheral tissues by releasing free fatty acids</td>
</tr>
<tr>
<td>Akt</td>
<td>A key regulator of insulin action and glucose uptake in mammals</td>
</tr>
<tr>
<td>IRS-1</td>
<td>Plays a key role in transmitting signals from insulin receptor to intracellular PI3K/Akt pathways and Ras/mitogen activated protein kinase, which eventually mediate various actions of insulin</td>
</tr>
<tr>
<td>PTP1B</td>
<td>A negative regulator of insulin signaling which targets tyrosine-phosphorylated insulin receptor β and IRS-1</td>
</tr>
<tr>
<td>mTOR</td>
<td>Inhibits IRS-1 tyrosine phosphorylation</td>
</tr>
</tbody>
</table>

1. GLUT: Glucose transporter; IL-6, Interleukin-6; NF-κB, Nuclear transcription factorκB; PPAR-γ, Peroxisome proliferator-activated receptor-gamma; TNFα, Tumor necrosis factor alpha; MCP-1, Monocyte chemoattractant protein-1; FFAs, free fatty acids; Akt, protein kinase B; IRS-1, insulin receptor substrate-1; PTP1B, protein-tyrosine phosphatase 1B; mTOR, mammalian target of rapamycin.
and over output hepatic glucose, and β-cell dysfunction are the most important reasons of hyperglycemia (22).

1.3.3. Hyperglycemia-Induced Tissue Damage

High flux of glucose across endothelial cell membranes is the initial point in the process of hyperglycemia-induced tissue damage. Increased glucose levels induce excess production of ROS, promote the protein kinase C (PKC) activity, and elevate the hexosamine pathway activation. Therefore, the generated oxidative stress can be responsible for the harmful effects of chronic hyperglycemia on pancreatic β-cell function. Additionally, pancreatic islets are chiefly composed of β cells and have the lowest antioxidant capacity among all metabolic tissues. Generally, it seems that over-productions of ROS and PKC mediate hyperglycemia-induced insulin resistance (23, 24). Moreover, hyperglycemia causes global or systemic effects such as vascular inflammation and immune system impairment by stimulating inflammatory cytokines and cell adhesion molecules and by inhibiting leukocyte function (18). This review summarized what is currently known about the effects of turmeric and its components on plasma glucose and insulin levels. Recent literature suggested that turmeric and its major component, curcumin, have antihyperglycemic and insulin sensitizer effects. We therefore aimed to present the putative mechanisms linking curcumin to blood glucose and insulin resistance.

2. Evidence Acquisition

The present study reviewed studies published from 1998 to 2013, indicating that curcumin attenuates many of the pathophysiological processes involved in development and progression of hyperglycemia and insulin resistance. It was based on a PubMed and Science Direct literature search using the following MeSH terminology and keywords: turmeric, curcumin, curcuminoids, Curcuma longa, hyperglycemia, blood glucose, insulin resistance, and hyperinsulinemia.

3. Results

3.1. Studies Conducted on the Effects of Curcumin on Blood Glucose Levels and Insulin Resistance

In vitro and in vivo studies are summarized in Table 2.

Table 2. Beneficial Effects of Supplementary Curcumin on Hyperglycemic Animal Models and High Glucose State Cell Culture

<table>
<thead>
<tr>
<th>Table 2. Beneficial Effects of Supplementary Curcumin on Hyperglycemic Animal Models and High Glucose State Cell Culture a</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>In Vivo/in Vitro experiment</strong></td>
</tr>
<tr>
<td><strong>STZ induced Diabetic Wistar rats (55 mg/kg)</strong></td>
</tr>
<tr>
<td><strong>high-fat diet+10 mg/kg STZ induced Diabetic Wistar rats (in vivo study)</strong></td>
</tr>
<tr>
<td><strong>L6 myotubes (in vitro experiment)</strong></td>
</tr>
<tr>
<td><strong>high fat diet induced Diabetic Sprague Dawley rats</strong></td>
</tr>
<tr>
<td><strong>Alloxan induced diabetic rats</strong></td>
</tr>
<tr>
<td><strong>Wild-type and ob/ob C57BL/6J mice</strong></td>
</tr>
<tr>
<td><strong>C57BL/KsJ ob/ob mice</strong></td>
</tr>
<tr>
<td>Type 2 Diabetic KK/Ay mice</td>
</tr>
<tr>
<td>--------------------------</td>
</tr>
<tr>
<td>In Vitro Experiments</td>
</tr>
<tr>
<td>STZ induced Diabetic rats</td>
</tr>
<tr>
<td>type 2 diabetic KK/Ay mice</td>
</tr>
<tr>
<td>Cell culture of Pancreas and muscle tissues of adult mice</td>
</tr>
<tr>
<td>Skeleton muscle isolated from Wistar rats</td>
</tr>
<tr>
<td>In vivo: STZ induced Diabetic Sprague-Dawley rats</td>
</tr>
<tr>
<td>In vitro: Primary peritoneal macrophages (MMP), prepared from C57BL/6 mice</td>
</tr>
<tr>
<td>Male Golden-Syrian hamsters</td>
</tr>
<tr>
<td>low dose of STZ + high energy intake induced diabetic Wistar rats</td>
</tr>
<tr>
<td>C57BL6 mice (5-6 weeks old)</td>
</tr>
</tbody>
</table>

* STZ, Streptozotocin; HG, high glucose; p-Akt, phosphoprotein kinase B; p-IR, phosphoinsulin receptor β; ER, endoplasmic reticulum; PTP1B, protein-tyrosine phosphatase 1B; TG, Triglyceride.
Elmoselhy et al. showed that prophylactic oral administration of curcumin (80 mg/kg) was comparable to rosiglitazone (1 mg/kg), which may indicate that they interact similarly (27).

Six-week administration of curcumin (0.02%, wt/wt) in ob/ob mice could increase the hepatic glucokinase activity and decrease glucose-6-phosphatase and phosphoenolpyruvate carboxykinase activities significantly. In ob/ob mice, curcumin significantly lowered the hepatic activities of fatty acid synthase, -oxidation, 3-hydroxy-3-methylglutaryl coenzyme reductase, and acyl-CoA cholesterol acyltransferase. Curcumin significantly lowered plasma free fatty acids, cholesterol, and triglyceride concentrations and increased the hepatic glycoprotein and skeletal muscle lipoprotein lipase in ob/ob mice. Curcumin normalized erythrocyte and hepatic antioxidant enzyme activities (superoxide dismutase, catalase, glutathione peroxidase) in ob/ob mice which resulted in a significant reduction in lipid peroxidation (30). In an experimental model of streptozocine (STZ)-induced diabetes, oral administration of curcumin at a dose of 100 mg/kg/day for 8 weeks, significantly corrected all the abnormalities induced by STZ injection and hyperglycemia, such as renal dysfunction, reduced creatinine clearance, increased blood glucose, blood urea nitrogen and proteinuria, and significant reduction in the body weight. Curcumin treatment significantly decreased macrophage infiltration in kidneys of diabetic rats, inhibited the expression of pro-inflammatory cytokines such as TNF-α and IL-1, and degradation of IκBα. Additionally, it significantly decreased ICAM-1, MCP-1, and TGF-β protein expressions. Moreover, at nuclear level, curcumin inhibited the NF-B activity (40).

Fujiiwara et al. showed that after 120 minutes of exposure to 25 mM curcumin, hepatic gluconeogenesis and glycogenolysis were inhibited significantly. Curcumin (25 mM) showed an additive inhibitory effect with insulin on both hepatic gluconeogenesis and glycogenolysis, indicating that it inhibits hepatic glucose production in an insulin-independent manner. After 120 minutes of exposure to 25 mM curcumin, hepatic glucose-6-phosphatase activity and phosphoenolpyruvate carboxykinase (PEPCK) activity were both inhibited by 30%. After 120 minutes of exposure to 25 mM curcumin, phosphorylation of AMP kinase a-Thr72 increased. They concluded that the antidiabetic effects of curcumin might be partly due to a reduction in hepatic glucose production caused by activation of AMP kinase and inhibition of G6Pase activity and PEPCK activity (41).

Pretreatment of pancreatic islets from C57BL6J mice with curcumin (10 mM) protected the islets from cytokine-induced islet death by scavenging ROS and normalized the cytokine production induced by NF-B translocation through inhibiting phosphorylation of inhibitor of kappa B alpha (IκBα). In addition, curcumin prevented STZ-induced diabetes, as manifested by sustained normoglycemia, had normal glucose clearance performance, and maintained pancreatic GLUT2 levels. Proinflammatory cytokine concentrations in serum and pancreas rose in STZ-treated animals, but not in animals pretreated with curcumin before STZ injection (42).

3.1.2. Curcumin, Cell Function and Insulin

Curcumin activated the volume-regulated anion channels in cells. This effect was accompanied by depolarization of the cell membrane potential, generation of electrical activity, and enhanced insulin release. Curcumin also decreased the cell volume, presumably reflecting loss of CI (and hence water) as a result of anion channel activation (43). In a recent study, administration of a new neuroprotective curcuminoid, CNB-001, improved intracellular insulin signaling, which was revealed by increased level of phosphoprotein kinase B (p-Akt), phosphor-insulin receptor (p-IR) β, as well as decreased level of endoplasmic reticulum (ER) stress, protein-tyrosine phosphatase 1B (PTP1B), and glucose uptake in gastrocnemius muscle of HFD fed mice (16).

3.1.3. The Curcumin Reduction Effects on Hyperglycemia-Induced Circulating ICAM-1, VCAM-1

Endothelial cells release multiple inflammatory mediators and express various adhesion molecules such as intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 (ICAM-1, VCAM-1). An acute increase of plasma glucose may lead to an oxidative stress, resulting in increased cellular expression of ICAM-1 (44). In another study, hyperglycemia triggered an inflammatory response in the retina of normolipidemic mice and up-regulated VCAM-1 in retinal vessels (45). Curcumin inhibits inflammation by blocking the adhesion of monocytes to endothelial cells. By inhibiting the activation of cell adhesion molecules ICAM-1 and VCAM-1 (11, 40).

3.2. Human Clinical Trials of Curcumin

Human clinical trials evaluating the effects of curcumin supplementation on blood glucose and insulin resistance are summarized in Table 3.

3.3. Schematic Roles of Curcumin in Reduction of Blood Glucose Level and Serum FFAs, Improvement of Inflammatory State and Decreasing Insulin Resistance

3.3.1. Reduction of Blood Glucose Level by Curcumin

AMPK pathway mediates the regulatory effect of curcumin on lipid and glucose oxidation and utilization, inhibits hepatic gluconeogenesis and glycogenolysis:

- Inhibits hepatic G6Pase and phosphoenolpyruvate carboxykinase (PEPCK) activity. Increases phosphorylation of AMP kinase (which leads to phosphorylation of G6Pase (GLUT4 enhance factor)). Inhibits PDK4 expression. Decreases glycogen synthesis. Reduces hepatic glucose production. Increases PPAR ligand-binding activity.
Figure 3. Antihyperglycemic and Anti-Insulin Resistance Effects of Curcumin

Table 3. Human Clinical Trials Evaluating the Effects of Curcumin Supplementation on Blood Glucose and Insulin Resistance

<table>
<thead>
<tr>
<th>Patients</th>
<th>Dose, Duration</th>
<th>Results In the End of the Study in Treatment Group</th>
<th>Overall Conclusion</th>
<th>Authors/Publication year</th>
<th>Reference Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>100 Overweight/obese type 2 diabetic patients</td>
<td>Curcuminoids (300 mg/day) 3 months</td>
<td>Fasting blood glucose ↓, insulin resistance index (HOMA-IR) ↓, serum total FFAs ↓, serum triglycerides ↓, LPL activity ↑</td>
<td>These findings indicate a glucose-lowering effect of Curcuminoids in type 2 diabetes, which is partially due to decrease in serum FFAs, which may result from promoting fatty acid oxidation and utilization</td>
<td>Na LX and colleagues/2012</td>
<td>(46)</td>
</tr>
<tr>
<td>subjects (n = 240) with criteria of prediabetes</td>
<td>six Curcumin capsules per day (Each capsule has Curcuminoid content of 250 mg) 9 months</td>
<td>16.4% of subjects in the placebo group were diagnosed with T2DM, whereas none were diagnosed with T2DM in the Curcumin-treated group. The Curcumin-treated group showed a better overall function of β-cells, HOMA-β ↑, C-peptide ↓, HOMA-IR ↓, Adiponectin ↑</td>
<td>Curcumin intervention in a pre-diabetic population significantly lowered the number of pre-diabetic individuals who eventually developed T2DM. In addition, the Curcumin treatment appeared to improve overall function of β-cells, with very minor adverse effects.</td>
<td>Chuengsamarn and colleagues/2012</td>
<td>(47)</td>
</tr>
<tr>
<td>Eleven healthy subjects, aged 21–38 y with normal fasting blood glucose (100 mg/dL) and total cholesterol (200 mg/dL) concentrations</td>
<td>a randomly assigned, crossover design: 6 subjects 3.0g cinnamon per day each treatment 4-wk</td>
<td>no significant changes in fasting plasma glucose or lipids in conjunction with the 4-wk periods of each treatment.</td>
<td>Maybe turmeric supplementation in healthy nondiabetic subjects did not reflect blood glucose-lowering effect</td>
<td>Tang M and colleagues/2008</td>
<td>(48)</td>
</tr>
<tr>
<td>60 subjects, 20 years old and above, who were diagnosed mild to moderate elevated ALT levels with normal glucose levels (91.9 ± 9.7)</td>
<td>fermented turmeric powder 3.0 g per day 12 weeks</td>
<td>reduction in ALT, AST levels no significant changes in blood glucose level</td>
<td>FTP is effective and safe, generally well-tolerated without severe adverse events, in the treatment of subjects with elevated ALT levels over a 12 weeks period</td>
<td>Kim SW and colleagues/2013</td>
<td>(49)</td>
</tr>
<tr>
<td>Fourteen healthy subjects in a crossover trial.</td>
<td>75 g oral glucose tolerance test (OGTT) together with capsules containing a placebo or C. longa (6 g)</td>
<td>no significant effect on the glucose response The insulin AUCs were significantly higher</td>
<td>The ingestion of 6 g C. longa increased postprandial serum insulin levels, but did not seem to affect plasma glucose levels or GI, in healthy subjects. The results indicate that C. longa may have an effect on insulin secretion</td>
<td>Wickenberg J and colleagues/2010</td>
<td>(47)</td>
</tr>
</tbody>
</table>

a HOMA-IR, insulin resistance index; OGTT, glucose tolerance test.
Increases phosphorylation of AKT (PKB), insulin receptor and IRS-1. Decreases FPIpB and HOMA-IR. Increases HOMA and improves cell function. Stimulates insulin secretion from pancreatic tissues. Increase GLUT4 and stimulates of glucose uptake. Reduces the oxidative stress and inflammatory state. Increases the adiponectin levels. Decreases HbA1c and blood glucosylation toward improving the insulin sensitivity and glucose control in skeletal muscle. Anti hyperglycemic and anti insulin resistance effects of curcumin are shown in Figure 3.

4. Conclusions
Curcumin can reduce blood glucose and HbA1c level by reduction in hepatic glucose production and glycoin synthesis and stimulation of glucose uptake by increasing GLUT4, GLUT2 and GLUT3 gene expressions, increasing activation of AMP kinase, promoting PPAR γ ligand-binding activity, suppressing hyperglycemia-induced inflammatory state, stimulation of insulin secretion from pancreatic tissues, improvement in pancreatic cell function, Increasing phosphorylation of AKT (PKB), insulin receptor β and reduction of insulin resistance. In human clinical trials conducted on diabetic and prediabetic patients, glucose lowering effect of turmeric and curcumin have been observed. However, no effect was seen in patients with normal baseline levels of blood sugar. More studies evaluating the effects of curcumin on hyperglycemic state and insulin resistance in related diseases such as diabetes are recommended.

Authors’ Contributions
Study concept and design, analysis and interpretation of data, drafting of the manuscript and revision of the manuscript for important intellectual content: Zeinab Ghorbani, Azita Hekmatdoost, and Parvin Mirmiran.

References


